Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Research Report 2024
According to Mr Accuracy reports’s new survey, global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market research.
Key manufacturers engaged in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) industry include Pfizer, Minhai Bio, Kexing Bio, Cansino Bio and Lanzhou Biological Preparations Institute, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer
Minhai Bio
Kexing Bio
Cansino Bio
Lanzhou Biological Preparations Institute
Segment by Type
Serotype 6B
7F Serotype
Serotype 9V
14 Serotype
Serotype 18C
Serotype 19A
19F Serotype
23F Serotype
24F Serotype
Other
Infants from 6 Weeks to 15 Months Old
Children Aged 15 Months to 5 Years
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Key manufacturers engaged in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) industry include Pfizer, Minhai Bio, Kexing Bio, Cansino Bio and Lanzhou Biological Preparations Institute, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Minhai Bio
Kexing Bio
Cansino Bio
Lanzhou Biological Preparations Institute
Segment by Type
Serotype 6B
7F Serotype
Serotype 9V
14 Serotype
Serotype 18C
Serotype 19A
19F Serotype
23F Serotype
24F Serotype
Other
Segment by Application
Infants from 6 Weeks to 15 Months Old
Children Aged 15 Months to 5 Years
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices